Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.20.8741

Genetic Polymorphism of Interleukin-1A (IL-1A), IL-1B, and IL-1 Receptor Antagonist (IL-1RN) and Prostate Cancer Risk  

Xu, Hua (Department of Urology, Huashan Hospital, Fudan University)
Ding, Qiang (Department of Urology, Huashan Hospital, Fudan University)
Jiang, Hao-Wen (Department of Urology, Huashan Hospital, Fudan University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.20, 2014 , pp. 8741-8747 More about this Journal
Abstract
Purpose: We aimed to investigate the associations between polymorphisms of interleukin-1A (IL-1A), IL-1B, and IL-1 receptor antagonist (IL-1RN) and prostate cancer (PCa) risk. Materials and Methods: A comprehensive search for articles of MEDLINE and EMBASE databases and bibliographies of retrieved articles published up to August 3, 2014 was performed. Methodological quality assessment of the trials was based on a standard quality scoring system. The meta-analysis was performed using STATA 12.0. Results: We included 9 studies (1 study for IL-1A, 5 studies for IL-1B, and 3 studies for IL-1RN), and significant association was found between polymorphisms of IL-1B-511 (rs16944) as well as IL-1B-31 (rs1143627) and PCa risk. IL-1B-511 (rs16944) polymorphism was significantly associated with PCa risk in homozygote and recessive models, as well as allele contrast (TT vs CC: OR, 0.74; 95%CI, 0.58-0.94; P=0.012; TT vs TC+CC; OR, 0.79; 95%CI, 0.63-0.98; P=0.033; T vs C: OR, 0.86; 95%CI, 0.77-0.96; P=0.008). The association between IL-1B-31 (rs1143627) polymorphism and PCa risk was weakly significant under a heterozygote model (OR, 1.35; 95%CI, 1.00-1.80; P=0.047). Conclusions: Sequence variants in IL-1B-511 (rs16944) and IL-1B-31 (rs1143627) are significantly associated with PCa risk, which provides additional novel evidence that proinflammatory cytokines and inflammation play an important role in the etiology of PCa.
Keywords
Prostate cancer; polymorphism; meta-analysis; interleukin-1; interleukin-1 receptor antagonist;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Nguyen DP, Li J, Yadav SS, et al (2014). Recent insights into NF-kappaB signalling pathways and the link between inflammation and prostate cancer. BJU Int, 114, 168-76.   DOI
2 Patel DA, Bock CH, Schwartz K, et al (2005). Sexually transmitted diseases and other urogenital conditions as risk factors for prostate cancer: a case--control study in Wayne County, Michigan. Cancer Causes Control, 16, 263-73.   DOI
3 Saenz-Lopez P, Carretero R, Cozar JM, et al (2008). Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 8, 382.   DOI   ScienceOn
4 Shao N, Xu B, Mi YY, et al (2011). IL-10 polymorphisms and prostate cancer risk: a meta-analysis. Prostate Cancer Prostatic Dis, 14, 129-35.   DOI
5 Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.   DOI   ScienceOn
6 Thakkinstian A, McEvoy M, Minelli C, et al (2005). Systematic review and meta-analysis of the association between {beta}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am J Epidemiol, 162, 201-11.   DOI   ScienceOn
7 Vignozzi L, Maggi M (2014). Prostate cancer: Intriguing data on inflammation and prostate cancer. Nat Rev Urol, 11, 369-70.   DOI
8 Wang MH, Helzlsouer KJ, Smith MW, et al (2009). Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate, 69, 874-85.   DOI
9 Yamamoto-Furusho JK, Santiago-Hernandez JJ, Perez-Hernandez N, et al (2011). Interleukin 1 beta (IL-1B) and IL-1 antagonist receptor (IL-1RN) gene polymorphisms are associated with the genetic susceptibility and steroid dependence in patients with ulcerative colitis. J Clin Gastroenterol, 45, 531-5.   DOI
10 Wang N, Zhou R, Wang C, et al (2012). -251 T/A polymorphism of the interleukin-8 gene and cancer risk: a HuGE review and meta-analysis based on 42 case-control studies. Mol Biol Rep, 39, 2831-41.   DOI   ScienceOn
11 Wang Y, Kato N, Hoshida Y, et al (2003). Interleukin-1beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology, 37, 65-71.   DOI
12 Xu J, Lowey J, Wiklund F, et al (2005). The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 14, 2563-8.   DOI   ScienceOn
13 Yang HP, Woodson K, Taylor PR, et al (2006). Genetic variation in interleukin 8 and its receptor genes and its influence on the risk and prognosis of prostate cancer among Finnish men in a large cancer prevention trial. Eur J Cancer Prev, 15, 249-53.   DOI
14 Yang M, Li C, Li M (2014). Association of interleukin-6 (-174 G/C) polymorphism with the prostate cancer risk: A metaanalysis. Biomed Rep, 2, 637-43.
15 Yu Z, Liu Q, Huang C, et al (2013). The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and metaanalysis of 73 studies including 15,942 cases and 22,336 controls. OMICS, 17, 200-14.   DOI   ScienceOn
16 Zabaleta J, Lin HY, Sierra RA, et al (2008). Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 29, 573-8.
17 Zabaleta J, Su LJ, Lin HY, et al (2009). Cytokine genetic polymorphisms and prostate cancer aggressiveness. Carcinogenesis, 30, 1358-62.   DOI
18 Zhang J, Dhakal IB, Lang NP, et al (2010). Polymorphisms in inflammatory genes, plasma antioxidants, and prostate cancer risk. Cancer Causes Control, 21, 1437-44.   DOI
19 Zienolddiny S, Ryberg D, Maggini V, et al (2004). Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer, 109, 353-6.   DOI
20 Apte RN, Voronov E (2008). Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev, 222, 222-41.   DOI
21 Baker SG, Lichtenstein P, Kaprio J, et al (2005). Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins. Biometrics, 61, 55-63.   DOI   ScienceOn
22 Bradley JR, Pober JS (2001). Tumor necrosis factor receptorassociated factors (TRAFs). Oncogene, 20, 6482-91.   DOI   ScienceOn
23 Cheng I, Krumroy LM, Plummer SJ, et al (2007). MIC1 and IL1RN genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 16, 1309-11.   DOI
24 Dinarello CA (1988). Biology of interleukin 1. FASEB J, 2, 108-15.
25 Dal Moro F, Zattoni F (2013). Inflammation and prostate cancer. Urol Oncol, 31, 712.   DOI
26 Dennis LK, Lynch CF, Torner JC (2002). Epidemiologic association between prostatitis and prostate cancer. Urology, 60, 78-83.
27 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI   ScienceOn
28 Dwivedi S, Goel A, Natu SM, et al (2011). Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Asian Pac J Cancer Prev, 12, 1843-8.
29 Dluzniewski PJ, Wang MH, Zheng SL, et al (2012). Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. Cancer Epidemiol Biomarkers Prev, 21, 1774-82.   DOI
30 Domingo-Domenech J, Oliva C, Rovira A, et al (2006). Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res, 12, 5578-86.   DOI   ScienceOn
31 Eeles R, Goh C, Castro E, et al (2014). The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol, 11, 18-31.
32 El-Omar EM, Carrington M, Chow WH, et al (2000). Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature, 404, 398-402.   DOI   ScienceOn
33 Guo YZ, Pan L, Du CJ, et al (2013). Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev, 14, 243-8.   과학기술학회마을   DOI   ScienceOn
34 Jim HS, Park JY, Permuth-Wey J, et al (2012). Genetic predictors of fatigue in prostate cancer patients treated with androgen deprivation therapy: preliminary findings. Brain Behav Immun, 26, 1030-6.   DOI
35 Guttridge DC, Albanese C, Reuther JY, et al (1999). NFkappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol, 19, 5785-99.
36 Ma L, Zhao J, Li T, et al (2014). Association between Tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol, 9, 74.   DOI
37 Hollegaard MV, Bidwell JL (2006). Cytokine gene polymorphism in human disease: on-line databases, Supplement 3. Genes Immun, 7, 269-76.   DOI   ScienceOn
38 Iwanaga R, Ozono E, Fujisawa J, et al (2008). Activation of the cyclin D2 and cdk6 genes through NF-kappaB is critical for cell-cycle progression induced by HTLV-I Tax. Oncogene, 27, 5635-42.   DOI
39 Lindmark F, Zheng SL, Wiklund F, et al (2005). Interleukin-1 receptor antagonist haplotype associated with prostate cancer risk. Br J Cancer, 93, 493-7.   DOI
40 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
41 McCarron SL, Edwards S, Evans PR, et al (2002). Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res, 62, 3369-72.
42 McIntyre KW, Stepan GJ, Kolinsky KD, et al (1991). Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med, 173, 931-9.   DOI
43 Ricote M, Garcia-Tunon I, Bethencourt FR, et al (2004). Interleukin-1 (IL-1alpha and IL-1beta) and its receptors (IL-1RI, IL-1RII, and IL-1Ra) in prostate carcinoma. Cancer, 100, 1388-96.   DOI   ScienceOn
44 Michaud DS, Daugherty SE, Berndt SI, et al (2006). Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res, 66, 4525-30.   DOI   ScienceOn